Special print on medicinal osteoporosis therapy

16.01.2013 14:53

Due to numerous inquiries regarding drug therapy for osteoporosis, the Bone Health Board has decided to publish a special print on this topic.

Osteoporosis (bone loss) is defined by low bone mass resulting in increased bone fragility. In Germany, 26% of the population over 50 years of age (= 7.8 million people) currently suffer from osteoporosis. Bone fragility is the result of reduced bone strength. The strength of a bone is determined by the bone mass, the material properties and the architecture, the arrangement and the networking of the bone trabeculae with each other. For good mineralization, the bone needs above all a sufficient supply of calcium, with the absorption of calcium from the intestine and the incorporation of calcium into the bone material being controlled by vitamin D.

If this basic care or basic therapy with calcium and vitamin D is guaranteed, then specific drug therapy is added. Osteoporosis medications target the bone changes in osteoporosis mentioned above. Ideal osteoporosis drugs are intended to increase bone mass, improve the connection of the bone trabeculae and also improve the bone material. These are high demands that today's medications can only partially meet. That's why it makes sense to use some medications in combination or in a chronological sequence.

In the new brochure from the Bone Health Board of Trustees, information on the chemical properties and mechanisms of action, pharmacokinetics (absorption, storage and excretion), clinical effects as well as possible side effects and contraindications are presented for the individual drug groups.

The brochure “Medicinal osteoporosis therapy – what you should know about it! Can be requested against an invoice (6.45 euros including 1.45 euros postage costs) from the Kuratorium Bone Health eV, Leipziger Straße 6, 74889 Sinsheim, Tel. 07261/9217-0 (Mon-Fri 8.30 a.m. - 12.30 p.m.) or by Email [email protected].